Literature DB >> 18544968

TP53 status and response to chemotherapy in breast cancer.

Philippe Bertheau1, Marc Espié, Elisabeth Turpin, Jacqueline Lehmann, Louis-François Plassa, Mariana Varna, Anne Janin, Hugues de Thé.   

Abstract

Despite its central role in the control of apoptosis, senescence and cell cycle arrest, the tumor suppressor protein p53 remains an enigma for its possible role in predicting response to chemotherapy in cancer patients. Many studies remained inconclusive, others showed a better response for tumors with normal p53, and some recent studies showed adverse effects of normal p53 for response to treatment. p53 is not only a powerful pro-apoptotic factor in response to drug-induced DNA damages but also a potential inducer of cell cycle arrest, protecting tumor cells from further cytotoxic damages. Our review describes the classical as well as the more recent concepts. In order to draw definite conclusions, future works should use more reliable methods to assess the TP53 status and should address more homogeneous tumor subpopulations treated with homogeneous chemotherapy regimens. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544968     DOI: 10.1159/000123851

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  47 in total

Review 1.  p53 regulation of metabolic pathways.

Authors:  Eyal Gottlieb; Karen H Vousden
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-02       Impact factor: 10.005

2.  Regulation of p53 stability and function by the deubiquitinating enzyme USP42.

Authors:  Andreas K Hock; Arnaud M Vigneron; Stephanie Carter; Robert L Ludwig; Karen H Vousden
Journal:  EMBO J       Date:  2011-11-15       Impact factor: 11.598

3.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

4.  Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.

Authors:  Tetsuyo Maeda; Yoko Nakanishi; Yukari Hirotani; Fumi Fuchinoue; Katsuhisa Enomoto; Kenichi Sakurai; Sadao Amano; Norimichi Nemoto
Journal:  Med Mol Morphol       Date:  2015-05-26       Impact factor: 2.309

Review 5.  The p53 pathway as a target in cancer therapeutics: obstacles and promise.

Authors:  Anna Mandinova; Sam W Lee
Journal:  Sci Transl Med       Date:  2011-01-05       Impact factor: 17.956

Review 6.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

7.  Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

Authors:  Elke J A H van Beek; Jonathan M Hernandez; Debra A Goldman; Jeremy L Davis; Kaitlin McLaughlin; R Taylor Ripley; Teresa S Kim; Laura H Tang; Jaclyn F Hechtman; Jian Zheng; Marinela Capanu; Nikolaus Schultz; David M Hyman; Marc Ladanyi; Michael F Berger; David B Solit; Yelena Y Janjigian; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2018-05-03       Impact factor: 5.344

8.  Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.

Authors:  Marjanka K Schmidt; Johanna Tommiska; Annegien Broeks; Flora E van Leeuwen; Laura J Van't Veer; Paul D P Pharoah; Douglas F Easton; Mitul Shah; Manjeet Humphreys; Thilo Dörk; Scarlett A Reincke; Rainer Fagerholm; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

9.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

10.  Proteomic analysis of regenerating mouse liver following 50% partial hepatectomy.

Authors:  Hongcui Cao; Jiong Yu; Wei Xu; Xiaofei Jia; Jinfeng Yang; Qiaoling Pan; Qiyi Zhang; Guoping Sheng; Jun Li; Xiaoping Pan; Yingjie Wang; Lanjuan Li
Journal:  Proteome Sci       Date:  2009-12-29       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.